Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a strategic agreement with Pearl Bio, a synthetic biology company, to leverage Pearl’s genomically recoded organisms (GROs) platform. This platform is designed for the discovery and development of biologic molecules that incorporate non-standard amino acids, enabling the targeting of previously inaccessible epitopes in oncology. Pearl’s innovative technology allows for the creation of multi-functionalized synthetic monomers with adjustable properties, potentially revolutionizing the development of novel biologics.
Under the terms of the agreement, MSD will make payments to Pearl totaling up to USD 1 billion, which includes an upfront fee, option payments, and milestone achievements. Additionally, Pearl stands to receive potential sales royalties from the collaboration.- Flcube.com
